111 Participants Needed

Novel Drug Combinations for Multiple Myeloma

Recruiting at 27 trial locations
BS
Fl
Overseen ByFirst line of the email MUST contain NCT # and Site #.
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is the novel drug combination for multiple myeloma safe for humans?

Iberdomide and Mezigdomide, both novel drugs being studied for multiple myeloma, have shown potential in preclinical models. However, specific safety data from human trials is not detailed in the provided research articles.12345

What makes the drug combination of Alnuctamab, BMS-986393, Iberdomide, and Mezigdomide unique for treating multiple myeloma?

This drug combination is unique because it includes novel cereblon E3 ligase modulators (CELMoDs) like Iberdomide and Mezigdomide, which have enhanced tumor-killing and immune-boosting effects compared to traditional treatments. These drugs are designed to work even in cases where other treatments, like lenalidomide, have failed, offering a new option for patients with relapsed or refractory multiple myeloma.12567

What data supports the effectiveness of the drug combinations involving Alnuctamab and other agents for treating multiple myeloma?

Research shows that Mezigdomide and Iberdomide, both part of the drug combinations, have demonstrated strong anti-cancer effects in multiple myeloma, even in cases resistant to other treatments. These drugs work by targeting specific proteins involved in cancer cell growth, making them promising options for patients with relapsed or hard-to-treat multiple myeloma.12678

Who Is on the Research Team?

BS

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Are You a Good Fit for This Trial?

This trial is for people with multiple myeloma that has come back or didn't respond to treatment. They must have had at least one but not more than three prior treatments and be in good physical condition. People can't join if their cancer has spread to the brain or they have other health issues that could affect the study results.

Inclusion Criteria

I have multiple myeloma that has come back or didn't respond to treatment, and I've had 1-3 prior treatments.
I am fully active or can carry out light work.
My multiple myeloma can be measured.

Exclusion Criteria

My multiple myeloma has affected or previously affected my brain or spinal cord.
You have a health condition that could make it hard to understand the study results.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive BMS-986393 in combination with either alnuctamab, mezigdomide, or iberdomide to establish a safe and tolerable dose

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Alnuctamab
  • BMS-986393
  • Iberdomide
  • Mezigdomide
Trial Overview The trial is testing BMS-986393 combined with alnuctamab, mezigdomide, and iberdomide to find a safe dose for patients whose multiple myeloma has relapsed or isn't responding to treatment.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Group I: Arm C: BMS-986393 + IberdomideExperimental Treatment2 Interventions
Group II: Arm B: BMS-986393 + MezigdomideExperimental Treatment2 Interventions
Group III: Arm A: BMS-986393 + AlnuctamabExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Lead Sponsor

Trials
19
Recruited
3,100+

Published Research Related to This Trial

In a phase 1-2 study involving 178 patients with relapsed and refractory multiple myeloma, the combination of mezigdomide and dexamethasone demonstrated an overall response rate of 41%, indicating promising efficacy for this treatment in heavily pretreated patients.
The most common side effects were neutropenia and infections, which were mostly reversible, suggesting that while the treatment has myelotoxic effects, it does not present unexpected toxicities.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.Richardson, PG., Trudel, S., Popat, R., et al.[2023]
Iberdomide combined with dexamethasone demonstrated meaningful clinical activity in heavily pretreated patients with relapsed or refractory multiple myeloma, achieving an overall response rate of 32% in the dose-escalation cohort and 26% in the dose-expansion cohort, indicating its potential effectiveness even in difficult-to-treat cases.
The treatment was generally safe, with a recommended phase 2 dose established at 1.6 mg, although some patients experienced serious adverse events, including neutropenia and infections, highlighting the need for careful monitoring during treatment.
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.Lonial, S., Popat, R., Hulin, C., et al.[2022]
Thalidomide and similar drugs are important treatments for multiple myeloma, as they target cereblon, a protein that plays a crucial role in protein degradation.
By binding to cereblon, these drugs change how the ubiquitin ligase complex works, leading to the destruction of Ikaros and Aiolos, which are key transcription factors needed for the growth of multiple myeloma cells.
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma.Licht, JD., Shortt, J., Johnstone, R.[2021]

Citations

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. [2023]
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. [2022]
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma. [2021]
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma. [2020]
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. [2021]
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival. [2020]
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. [2018]
CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security